Synthesis of Novel Water-Soluble Glycodendrimers as Anti-HIV Agents

作为抗 HIV 药物的新型水溶性糖聚合物的合成

基本信息

项目摘要

DESCRIPTION (provided by applicant): The goal of the proposed research entails the synthesis of glycodendrimers capable of binding to the HIV surface protein gp120, and blocking subsequent interactions with the host cell leading up to viral entry. Gp120 is present on the surface of HIV complexed with membrane protein gp41 as a heterotrimer. The gp120/gp41 complex, upon binding to cell surface CD4, undergoes a conformational change, exposing the N-terminal region of gp41. Gp120 next binds cell surface co-receptors via electrostatic interactions, that strengthen the virus-host cell interactions, allowing for subsequent gp41 fusion, pore formation, and ultimately, viral entry. It has been reported that the viral fusion/entry process is cooperative, requiring multiple copies of CD4, host cell co-receptors, and clustering of the gp41/gp120 heterotrimer. Due to the multivalent nature of the viral fusion/entry process, it is hypothesized that the glycodendrimers will be capable of binding to multiple copies of gp120 simultaneously, preventing viral entry. The shape, number of carbohydrates, and size of the glycodendrimers are expected to be the significant contributing factors determining the anti-HIV activity. The hypothesis will be tested through accomplishment of four specific aims. SA#1 describes the synthesis of interchangeable dendrimer linkers and differentially branched cores. SA#2 outlines the synthesis of discrete carbohydrate-linker conjugates, primed for coupling to the branched dendrimer cores. SA#3 depicts the construction of a variety of branched glycodendrimers to evaluate the specific architectural features necessary for optimum binding to gp120, and inhibition of viral infectivity, which will be evaluated in the fourth specific aim (SA#4). Preliminary research indicates that the synthetic methodologies are sound and that the target glycodendrimers can be synthesized and evaluated for their anti-HIV properties within the timeframe of the project. The proposed research seeks to fill a void in the anti- HIV drug arsenal by providing lead compounds specifically targeting viral gp120. Relevance: In the U.S., there are 850,000-950,000 HIV-infected people, with an additional 180,000-280,000 unaware they are HIV-positive. Due to adverse side-effects and decreased drug effectiveness caused by viral resistance, the development of new anti-HIV drugs is crucial in maintaining longevity and quality of life for infected individuals. This research seeks to develop a new class of anti-HIV drugs.
描述(由申请人提供):拟议研究的目标是合成能够与HIV表面蛋白gp 120结合的糖树枝状聚合物,并阻断随后与宿主细胞的相互作用,导致病毒进入。Gp 120作为异源三聚体存在于与膜蛋白gp 41复合的HIV表面上。gp 120/gp 41复合物在与细胞表面CD 4结合后发生构象变化,暴露gp 41的N-末端区域。gp 120接下来通过静电相互作用结合细胞表面共受体,这加强了病毒-宿主细胞相互作用,允许随后的gp 41融合、孔形成和最终的病毒进入。据报道,病毒融合/进入过程是协同的,需要多个拷贝的CD 4、宿主细胞共受体和gp 41/gp 120异源三聚体的聚集。由于病毒融合/进入过程的多价性质,假设糖树枝状聚合物将能够同时结合gp 120的多个拷贝,防止病毒进入。预计糖树枝状聚合物的形状、碳水化合物的数量和大小是决定抗HIV活性的重要因素。将通过实现四个具体目标来检验这一假设。SA#1描述了可互换的树枝状聚合物接头和差异支化核的合成。SA#2概述了离散的碳水化合物-接头缀合物的合成,其被引发用于偶联至支链树枝状聚合物核心。SA#3描述了多种支链糖树枝状聚合物的构建,以评价与gp 120的最佳结合和病毒感染性抑制所需的特定结构特征,这将在第四个具体目标(SA#4)中进行评价。初步研究表明,合成方法是合理的,目标glycodendrimers可以合成和评估其抗艾滋病毒特性的项目的时间范围内。这项拟议中的研究试图通过提供专门针对病毒gp 120的先导化合物来填补抗艾滋病毒药物库中的空白。相关性:在美国,有850 000 - 950 000艾滋病毒感染者,另有180 000 - 280 000人不知道他们是艾滋病毒阳性。由于病毒耐药性引起的不良副作用和药物有效性降低,开发新的抗HIV药物对于维持感染者的寿命和生活质量至关重要。这项研究旨在开发一种新的抗艾滋病毒药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHERINE D MCREYNOLDS其他文献

KATHERINE D MCREYNOLDS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHERINE D MCREYNOLDS', 18)}}的其他基金

Glycopolymer Inhibitors of Heparan Sulfate Proteoglycan Binding Pathogens
硫酸乙酰肝素蛋白多糖结合病原体的糖聚合物抑制剂
  • 批准号:
    10684252
  • 财政年份:
    2016
  • 资助金额:
    $ 19.8万
  • 项目类别:
Development of Glycodendrimers as Potential Anti-HIV Microbicide Agents
糖树聚合物作为潜在抗 HIV 杀菌剂的开发
  • 批准号:
    9140913
  • 财政年份:
    2016
  • 资助金额:
    $ 19.8万
  • 项目类别:
Glycopolymer Inhibitors of Heparan Sulfate Proteoglycan Binding Pathogens
硫酸乙酰肝素蛋白多糖结合病原体的糖聚合物抑制剂
  • 批准号:
    10491359
  • 财政年份:
    2016
  • 资助金额:
    $ 19.8万
  • 项目类别:
Development of Glycodendrimers as Potential Anti-HIV Microbicide Agents
糖树聚合物作为潜在抗 HIV 杀菌剂的开发
  • 批准号:
    9247821
  • 财政年份:
    2016
  • 资助金额:
    $ 19.8万
  • 项目类别:
Glycopolymer Inhibitors of Heparan Sulfate Proteoglycan Binding Pathogens
硫酸乙酰肝素蛋白多糖结合病原体的糖聚合物抑制剂
  • 批准号:
    10333201
  • 财政年份:
    2016
  • 资助金额:
    $ 19.8万
  • 项目类别:
Synthesis of Novel Water-Soluble Glycodendrimers as Anti-HIV Agents
作为抗 HIV 药物的新型水溶性糖聚合物的合成
  • 批准号:
    7848773
  • 财政年份:
    2009
  • 资助金额:
    $ 19.8万
  • 项目类别:
Synthesis of Novel Water-Soluble Glycodendrimers as Anti-HIV Agents
作为抗 HIV 药物的新型水溶性糖聚合物的合成
  • 批准号:
    7278054
  • 财政年份:
    2006
  • 资助金额:
    $ 19.8万
  • 项目类别:

相似海外基金

Biochemistry of Platelet Desialylation
血小板脱唾液酸化的生物化学
  • 批准号:
    10833844
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
个体化疫苗免疫疗法联合抗 PD 1 抗体治疗复发性或转移性头颈部鳞状细胞癌
  • 批准号:
    10658577
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Develop a human liver system to study SLC25A13 mutations in citrin deficiency
开发人类肝脏系统来研究柠檬酸缺乏症中的 SLC25A13 突变
  • 批准号:
    10724616
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Plant-Focused Nutrition in Patients with Diabetes and Chronic Kidney Disease (PLAFOND Study): A Pilot/Feasibility Study
糖尿病和慢性肾病患者的植物性营养(PLAFOND 研究):试点/可行性研究
  • 批准号:
    10586677
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Caries resistance mechanisms in high-risk Indigenous children
高危原住民儿童的防龋机制
  • 批准号:
    10639704
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Alleviating carbohydrate counting in adults with type 1 diabetes with weekly Semaglutide injections added to an automated insulin delivery with Lyumjev
通过每周注射索马鲁肽并添加 Lyumjev 自动胰岛素输送来减少 1 型糖尿病成人患者的碳水化合物计数
  • 批准号:
    10636689
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
系统性产生 MPS IIIA(桑菲利波 A 综合征)的脑穿透替代酶的基因疗法
  • 批准号:
    10760336
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Minimally-invasive technology for personalized nutritional monitoring
用于个性化营养监测的微创技术
  • 批准号:
    10693521
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Vanderbilt Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes
范德比尔特肥胖和糖尿病活体模型代谢表型中心
  • 批准号:
    10588959
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
Vitamin D Receptor Regulation of Microbiota in Intestinal Epithelia
维生素 D 受体对肠上皮微生物群的调节
  • 批准号:
    10736407
  • 财政年份:
    2023
  • 资助金额:
    $ 19.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了